PI3K Pathway Activation Markers in ER-Positive, HER2-Negative Breast Cancer: A Clinicopathologic Study

计划入组 70 人 · 首次发布于 2026 年 2 月 4 日

BKM120 for Patients With PI3K-activated Tumors

计划入组 146 人 · 首次发布于 2013 年 4 月 16 日

The Growth Factor Signature (GFS) as an Intermediate Biomarker of Response for Development of PI3K-Pathway Inhibitors in Patients With Breast Cancer (MK-8669-050)

计划入组 63 人 · 首次发布于 2010 年 10 月 14 日

BVD-PI3K gamma

IHMT-PI3K-455

PI3K inhibitor (cancer)

Pathway Therapeutics, Inc.

United States

Erasca

United States

Eledon Pharmaceuticals

United States

Sensei Biotherapeutics Acquires Faeth Therapeutics for $200M to Advance PI3K/AKT/mTOR Pathway Inhibitor PIKTOR

Paxalisib Plus Radiotherapy Shows Promise in Brain Metastases with PI3K Mutations

Sysmex Inostics' RAS-RAF-SEQ Assay Gains New York Approval for Clinical Trial Use